Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CHKA | P35790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29160731 | 0.82 | CA2 (0.33) | ANPEPERAP2CA2CA12CA1 | |
| SCHEMBL227948 | 0.82 | CA2 (0.33) | ANPEPERAP2CA2CA12CA1 | |
| SCHEMBL18584736 | 0.82 | — | — | |
| SCHEMBL28634205 | 0.82 | — | — | |
| Water SCHEMBL11853077 | 0.80 | CA2 (0.32) | ANPEPERAP2CA2CA12CA1 | |
| SCHEMBL27567916 | 0.79 | FDPS (0.34) | ANPEPERAP2 | |
| SCHEMBL28306346 | 0.78 | CA2 (0.31) | ANPEPERAP2CA2CA12CA1 | |
| Hydrochloric Acid SCHEMBL27950022 | 0.78 | CA2 (0.31) | ANPEPERAP2CA2CA12CA1 | |
| SCHEMBL11128978 | 0.77 | CA2 (0.31) | CA2CA12CA1CA9CHKA | |
| SCHEMBL225178 | 0.75 | FDPS (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9982261-B2 | Antisense antiviral compounds and methods for treating a filovirus infection | SAREPTA THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170306323-A1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-10-26 | — | — | US | disclosed |
| EP-2024499-B1 | OLIGONUCLEOTIDE ANALOGS HAVING CATIONIC INTERSUBUNIT LINKAGES | SAREPTA THERAPEUTICS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3205342-A1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | Sarepta Therapeutics, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2735568-B1 | Oligonucleotide analogs having cationic intersubunit linkages | AVI BIOPHARMA INC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-2603220-B1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | SAREPTA THERAPEUTICS INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9382536-B2 | Antisense antiviral compounds and methods for treating a filovirus infection | SAREPTA THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150275204-A1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2015-10-01 | — | — | US | disclosed |
| EP-2735568-A1 | Oligonucleotide analogs having cationic intersubunit linkages | AVI BioPharma, Inc. (US) | 2014-05-28 | — | — | EP | disclosed |
| US-8703735-B2 | Antisense antiviral compounds and methods for treating a filovirus infection | SAREPTA THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20090186847-A1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | SAREPTA THERAPEUTICS, INC. | 2009-07-23 | — | — | US | disclosed |
| US-7524829-B2 | Antisense antiviral compounds and methods for treating a filovirus infection | AVI BIOPHARMA, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20090088562-A1 | Oligonucleotide analogs having cationic intersubunit linkages | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2009-04-02 | — | — | US | disclosed |
| US-7507196-B2 | Antisense antiviral compounds and methods for treating a filovirus infection | AVI BIOPHARMA, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-2024499-A2 | OLIGONUCLEOTIDE ANALOGS HAVING CATIONIC INTERSUBUNIT LINKAGES | Avi Biopharma, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008036127-A2 | OLIGONUCLEOTIDE ANALOGS HAVING CATIONIC INTERSUBUNIT LINKAGES | AVI BIOPHARMA, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| EP-1814596-A2 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING FILOVIRUS INFECTION | Avi Biopharma, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060281701-A1 | Antisense antiviral compounds and methods for treating a filovirus infection | SAREPTA THERAPEUTICS, INC. | 2006-12-14 | — | — | US | disclosed |
| US-20060205693-A1 | Antisense antiviral compounds and methods for treating a filovirus infection | SAREPTA THERAPEUTICS, INC. | 2006-09-14 | — | — | US | disclosed |
| WO-2006050414-A2 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING FILOVIRUS INFECTION | AVI BIOPHARMA, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170306323-A1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | HNRNPU, MED25, SSU72 | ANPEP 353/4885ERAP2 512/4885CA2 4338/4885 |
| US-20150275204-A1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | HNRNPU, MED25, SSU72 | ANPEP 353/4885ERAP2 512/4885CA2 4338/4885 |
| US-20060205693-A1 | Antisense antiviral compounds and methods for treating a filovirus infection | MED25, UPF1, RNGTT | ANPEP 733/4885ERAP2 1506/4885CA2 4497/4885 |
| US-20060281701-A1 | Antisense antiviral compounds and methods for treating a filovirus infection | UPF1, NSUN2, RNGTT | ANPEP 806/4885ERAP2 1365/4885CA2 4405/4885 |
| US-20090186847-A1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | RNGTT, POLM, EIF2AK2 | ANPEP 372/4885ERAP2 900/4885CA2 4257/4885 |
| US-20090088562-A1 | Oligonucleotide analogs having cationic intersubunit linkages | SLC38A7, SLC43A3, SLC28A3 | ANPEP 569/4885ERAP2 669/4885CA2 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.